178 related articles for article (PubMed ID: 31882686)
1. Reduction in the Incidence of Urological Cancers after the Ban on Chinese Herbal Products Containing Aristolochic Acid: An Interrupted Time-Series Analysis.
Jhuang JR; Chiang CJ; Su SY; Yang YW; Lee WC
Sci Rep; 2019 Dec; 9(1):19860. PubMed ID: 31882686
[TBL] [Abstract][Full Text] [Related]
2. Population-based case-control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk.
Lai MN; Wang SM; Chen PC; Chen YY; Wang JD
J Natl Cancer Inst; 2010 Feb; 102(3):179-86. PubMed ID: 20026811
[TBL] [Abstract][Full Text] [Related]
3. Re: Population-based case-control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk.
Su YC; Lin JS; Lee MT; Li TC; Lee SM
J Natl Cancer Inst; 2010 Jul; 102(13):988; author reply 988-90. PubMed ID: 20479292
[No Abstract] [Full Text] [Related]
4. Increased risk of urinary tract cancer in ESRD patients associated with usage of Chinese herbal products suspected of containing aristolochic acid.
Wang SM; Lai MN; Wei A; Chen YY; Pu YS; Chen PC; Wang JD
PLoS One; 2014; 9(8):e105218. PubMed ID: 25170766
[TBL] [Abstract][Full Text] [Related]
5. Increased mortality risk for cancers of the kidney and other urinary organs among Chinese herbalists.
Yang HY; Wang JD; Lo TC; Chen PC
J Epidemiol; 2009; 19(1):17-23. PubMed ID: 19164871
[TBL] [Abstract][Full Text] [Related]
6. Aristolochic acid-induced upper tract urothelial carcinoma in Taiwan: clinical characteristics and outcomes.
Chen CH; Dickman KG; Huang CY; Moriya M; Shun CT; Tai HC; Huang KH; Wang SM; Lee YJ; Grollman AP; Pu YS
Int J Cancer; 2013 Jul; 133(1):14-20. PubMed ID: 23292929
[TBL] [Abstract][Full Text] [Related]
7. Aristolochic acid-containing Chinese herbal medicine and upper urinary tract urothelial carcinoma in Taiwan: a narrative review.
Dickman KG; Chen CH; Grollman AP; Pu YS
World J Urol; 2023 Apr; 41(4):899-907. PubMed ID: 35867141
[TBL] [Abstract][Full Text] [Related]
8. Trends in the incidence of urothelial carcinoma in Taiwan after the ban on aristolochic acid-containing Chinese herbal preparations, 2001-2018: a national population-based cohort study.
Liao CI; Fang HC; Lee PT; Hsu CY; Chen CL; Huang CW; Chen XY; Ou SH; Tsai CT; Chou KJ
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8201-8211. PubMed ID: 37061628
[TBL] [Abstract][Full Text] [Related]
9. Aristolochic Acid in the Etiology of Renal Cell Carcinoma.
Hoang ML; Chen CH; Chen PC; Roberts NJ; Dickman KG; Yun BH; Turesky RJ; Pu YS; Vogelstein B; Papadopoulos N; Grollman AP; Kinzler KW; Rosenquist TA
Cancer Epidemiol Biomarkers Prev; 2016 Dec; 25(12):1600-1608. PubMed ID: 27555084
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in upper tract urothelial carcinomas: From bench to clinics.
Shao IH; Chang YH; Pang ST
Int J Urol; 2019 Feb; 26(2):148-159. PubMed ID: 30372791
[TBL] [Abstract][Full Text] [Related]
11. Chinese herbs containing aristolochic acid associated with renal failure and urothelial carcinoma: a review from epidemiologic observations to causal inference.
Yang HY; Chen PC; Wang JD
Biomed Res Int; 2014; 2014():569325. PubMed ID: 25431765
[TBL] [Abstract][Full Text] [Related]
12. Aristolochic acid and its effect on different cancers in uro-oncology.
Rebhan K; Ertl IE; Shariat SF; Grollman AP; Rosenquist T
Curr Opin Urol; 2020 Sep; 30(5):689-695. PubMed ID: 32701724
[TBL] [Abstract][Full Text] [Related]
13. Mutational signature of aristolochic acid: Clue to the recognition of a global disease.
Rosenquist TA; Grollman AP
DNA Repair (Amst); 2016 Aug; 44():205-211. PubMed ID: 27237586
[TBL] [Abstract][Full Text] [Related]
14. Aristolochic acid nephropathy: Harbinger of a global iatrogenic disease.
Grollman AP
Environ Mol Mutagen; 2013 Jan; 54(1):1-7. PubMed ID: 23238808
[TBL] [Abstract][Full Text] [Related]
15. Increased risks of upper tract urothelial carcinoma in male and female chinese herbalists.
Yang HY; Wang JD; Lo TC; Chen PC
J Formos Med Assoc; 2011 Mar; 110(3):161-8. PubMed ID: 21497279
[TBL] [Abstract][Full Text] [Related]
16. Aristolochic acid-associated urothelial cancer in Taiwan.
Chen CH; Dickman KG; Moriya M; Zavadil J; Sidorenko VS; Edwards KL; Gnatenko DV; Wu L; Turesky RJ; Wu XR; Pu YS; Grollman AP
Proc Natl Acad Sci U S A; 2012 May; 109(21):8241-6. PubMed ID: 22493262
[TBL] [Abstract][Full Text] [Related]
17. [Aristolochic acid nephropathy ("Chinese herb nephropathy")].
Nortier J; Pozdzik A; Roumeguere T; Vanherweghem JL
Nephrol Ther; 2015 Dec; 11(7):574-88. PubMed ID: 26515658
[TBL] [Abstract][Full Text] [Related]
18. Aristolochic acid nephropathy: a worldwide problem.
Debelle FD; Vanherweghem JL; Nortier JL
Kidney Int; 2008 Jul; 74(2):158-69. PubMed ID: 18418355
[TBL] [Abstract][Full Text] [Related]
19. Aristolochic acid nephropathy.
Gökmen MR; Lord GM
BMJ; 2012 Jun; 344():e4000. PubMed ID: 22705815
[No Abstract] [Full Text] [Related]
20. Renal cell carcinomas of chronic kidney disease patients harbor the mutational signature of carcinogenic aristolochic acid.
Jelaković B; Castells X; Tomić K; Ardin M; Karanović S; Zavadil J
Int J Cancer; 2015 Jun; 136(12):2967-72. PubMed ID: 25403517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
